MGX (STOCKS)
Metagenomi Therapeutics, Inc. Common Stock
$1.230000
+0.010000 (+0.82%)
Prev close: $1.220000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jian Irish
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $46.85M
- Employees
- 171
- P/E (TTM)
- -0.49
- P/B (TTM)
- 0.41
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.61 | $-0.53 | -0.0781 | -14.68% |
|
Dec 2025 (Q4)
|
$-0.60 | $-0.61 | +0.0115 | +1.88% |
|
Sep 2025 (Q3)
|
$-0.55 | $-0.59 | +0.0398 | +6.75% |
|
Jun 2025 (Q2)
|
$-0.54 | $-0.63 | +0.0872 | +13.90% |
Financial Statements
| Revenues | $13.56M |
| Benefits Costs and Expenses | $107.21M |
| Costs And Expenses | $110.04M |
| Nonoperating Income/Loss | $6.91M |
| Operating Expenses | $114.13M |
| Research and Development | $88.60M |
| Other Operating Expenses | $25.53M |
| Operating Income/Loss | -$100.57M |
| Income/Loss From Continuing Operations After Tax | -$93.46M |
| Income/Loss From Continuing Operations Before Tax | -$93.65M |
| Income Tax Expense/Benefit | -$190.00K |
| Net Income/Loss | -$93.46M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$93.46M |
| Net Income/Loss Available To Common Stockholders, Basic | -$93.46M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.49 |
| Diluted Earnings Per Share | -$2.49 |
| Basic Average Shares | 75,044,023 |
| Diluted Average Shares | 75,044,023 |
| Assets | $173.70M |
| Current Assets | $124.47M |
| Cash | $120.70M |
| Other Current Assets | $3.77M |
| Noncurrent Assets | $49.23M |
| Fixed Assets | $9.90M |
| Other Non-current Assets | $39.34M |
| Liabilities | $61.13M |
| Current Liabilities | $27.63M |
| Accounts Payable | $2.60M |
| Other Current Liabilities | $25.03M |
| Noncurrent Liabilities | $33.50M |
| Equity | $112.57M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $112.57M |
| Liabilities And Equity | $173.70M |
| Net Cash Flow From Operating Activities | -$85.49M |
| Net Cash Flow From Operating Activities, Continuing | -$85.49M |
| Net Cash Flow From Investing Activities | $96.88M |
| Net Cash Flow From Investing Activities, Continuing | $96.88M |
| Net Cash Flow From Financing Activities | -$73.00K |
| Net Cash Flow From Financing Activities, Continuing | -$73.00K |
| Net Cash Flow | $11.32M |
| Net Cash Flow, Continuing | $11.32M |
| Comprehensive Income/Loss | -$93.65M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$93.96M |
| Other Comprehensive Income/Loss | -$48.07M |
| Other Comprehensive Income/Loss Attributable To Parent | -$494.00K |